These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 21811937)

  • 21. A validated high-throughput UHPLC-MS/MS assay for accurate determination of rivaroxaban in plasma sample.
    Iqbal M; Khalil NY; Imam F; Khalid Anwer M
    J Thromb Thrombolysis; 2015 Jan; 39(1):79-88. PubMed ID: 25106734
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Determination of an international sensitivity index of thromboplastin reagents using a WHO thromboplastin as calibrator for plasma spiked with rivaroxaban.
    Harenberg J; Marx S; Krämer R; Giese C; Weiss C
    Blood Coagul Fibrinolysis; 2011 Dec; 22(8):637-41. PubMed ID: 21986465
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Measurement of dabigatran, rivaroxaban and apixaban in samples of plasma, serum and urine, under real life conditions. An international study.
    Harenberg J; Du S; Wehling M; Zolfaghari S; Weiss C; Krämer R; Walenga J
    Clin Chem Lab Med; 2016 Feb; 54(2):275-83. PubMed ID: 26167981
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preincubation in the Prothrombinase-induced Clotting Time test (PiCT) is necessary for in vitro evaluation of fondaparinux and to be avoided for the reversible, direct factor Xa inhibitor, rivaroxaban.
    Kluft C; Meijer P; Kret R; Burggraaf J
    Int J Lab Hematol; 2013 Aug; 35(4):379-84. PubMed ID: 23151091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study.
    Agnelli G; Gallus A; Goldhaber SZ; Haas S; Huisman MV; Hull RD; Kakkar AK; Misselwitz F; Schellong S;
    Circulation; 2007 Jul; 116(2):180-7. PubMed ID: 17576867
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect on Plasma Protein S Activity in Patients Receiving the Factor Xa Inhibitors.
    Terakami T; Nagaya S; Hayashi K; Furusho H; Fujino N; Kato T; Asakura H; Morishita E
    J Atheroscler Thromb; 2022 Jul; 29(7):1059-1068. PubMed ID: 34334529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rivaroxaban: population pharmacokinetic analyses in patients treated for acute deep-vein thrombosis and exposure simulations in patients with atrial fibrillation treated for stroke prevention.
    Mueck W; Lensing AW; Agnelli G; Decousus H; Prandoni P; Misselwitz F
    Clin Pharmacokinet; 2011 Oct; 50(10):675-86. PubMed ID: 21895039
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of a Heparin-Calibrated Antifactor Xa Assay for Measuring the Anticoagulant Effect of Oral Direct Xa Inhibitors.
    Beyer J; Trujillo T; Fisher S; Ko A; Lind SE; Kiser TH
    Clin Appl Thromb Hemost; 2016 Jul; 22(5):423-8. PubMed ID: 26842561
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Measuring Rivaroxaban in a clinical laboratory setting, using common coagulation assays, Xa inhibition and thrombin generation.
    Molenaar PJ; Dinkelaar J; Leyte A
    Clin Chem Lab Med; 2012 Oct; 50(10):1799-807. PubMed ID: 23089710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of the oral, direct factor Xa inhibitor edoxaban on routine coagulation assays, lupus anticoagulant and anti-Xa assays.
    Hillarp A; Strandberg K; Baghaei F; Fagerberg Blixter I; Gustafsson KM; Lindahl TL
    Scand J Clin Lab Invest; 2018; 78(7-8):575-583. PubMed ID: 30278787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Can an anti-Xa assay for unfractionated heparin be used to assess the presence of rivaroxaban in critical situations?
    Shin H; Koh EH; Lee GW; Song HN; Kim HY; Park S
    J Vasc Surg Venous Lymphat Disord; 2020 Sep; 8(5):741-747. PubMed ID: 32113855
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Evaluation of a chromogenic assay to measure the factor Xa inhibitory activity of unfractionated heparin in canine plasma.
    Brooks MB
    Vet Clin Pathol; 2004; 33(4):208-14. PubMed ID: 15570557
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of rivaroxaban--an oral, direct factor Xa inhibitor.
    Kreutz R
    Curr Clin Pharmacol; 2014 Feb; 9(1):75-83. PubMed ID: 24218999
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The mechanism of action of rivaroxaban--an oral, direct Factor Xa inhibitor--compared with other anticoagulants.
    Samama MM
    Thromb Res; 2011 Jun; 127(6):497-504. PubMed ID: 20888031
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Accuracy and consistency of anti-Xa activity measurement for determination of rivaroxaban plasma levels.
    Studt JD; Alberio L; Angelillo-Scherrer A; Asmis LM; Fontana P; Korte W; Mendez A; Schmid P; Stricker H; Tsakiris DA; Wuillemin WA; Nagler M
    J Thromb Haemost; 2017 Aug; 15(8):1576-1583. PubMed ID: 28574652
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DOAC plasma levels measured by chromogenic anti-Xa assays and HPLC-UV in apixaban- and rivaroxaban-treated patients from the START-Register.
    Cini M; Legnani C; Padrini R; Cosmi B; Dellanoce C; De Rosa G; Marcucci R; Pengo V; Poli D; Testa S; Palareti G
    Int J Lab Hematol; 2020 Apr; 42(2):214-222. PubMed ID: 32039550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Report of the Subcommittee of Control of Anticoagulation on the determination of the anticoagulant effects of rivaroxaban.
    Harenberg J; Marx S; Weiss C; Krämer R; Samama M; Schulman S;
    J Thromb Haemost; 2012 Jul; 10(7):1433-6. PubMed ID: 22947062
    [No Abstract]   [Full Text] [Related]  

  • 38. Limitations of Specific Coagulation Tests for Direct Oral Anticoagulants: A Critical Analysis.
    Ebner M; Birschmann I; Peter A; Härtig F; Spencer C; Kuhn J; Rupp A; Blumenstock G; Zuern CS; Ziemann U; Poli S
    J Am Heart Assoc; 2018 Oct; 7(19):e009807. PubMed ID: 30371316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay.
    Barrett YC; Wang Z; Frost C; Shenker A
    Thromb Haemost; 2010 Dec; 104(6):1263-71. PubMed ID: 20978714
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Measuring residual anti-Xa activity of direct factor Xa inhibitors after reversal with andexanet alfa.
    Bourdin M; Perrotin D; Mathieu O; Herve T; Depasse F; Lu G; Conley PB; Contant G
    Int J Lab Hematol; 2021 Aug; 43(4):795-801. PubMed ID: 34092030
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.